Joseph Anderson, Ph.D.

Clinical Interests	My research interests are in HIV stem cell gene therapy and focus on translating key research findings into clinical applications for the treatment of infected individuals.
Title	Assistant Adjunct Professor
Specialty	Infectious Diseases, Internal Medicine
Department	Internal Medicine
Division	Infectious Diseases
Center/Program Affiliation	Northern California Center for AIDS Research
Education	Ph.D., Colorado State University, Fort Collins, Colorado, 2005 B.S., University of Wisconsin, La Crosse , Wisconsin, 2000
Professional Memberships	American Society of Gene and Cellular Therapy
Honors and Awards	Acceptance into the UC Davis Mentored Clinical Research Training Program., 2013 First place award for poster at "Medical Student Research and Poster Forum" at UC-Davis Medical Center, Symposium, 2009 American Society of Hematology Travel Award for abstract poster presentation at ASH conference, 2008
Select Recent Publications	Kalomoiris S, Lawson J, Chen RX, Bauer G, Nolta JA, and Anderson JS. CD25 preselective anti-HIV vectors for improved HIV gene therapy. Human Gene Therapy Methods, 2012;23: 366-375. Anderson JS and Bauer G. Fighting HIV with stem cell therapy: one step closer to human trials? Expert Review of Anti-Infective Therapy, 2012;10: 1071-1073. Walker JE, Chen RX, McGee J, Nacey C, Pollard RB, Abedi M, Bauer G, Nolta JA, and Anderson JS. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. Journal of Virology, 2012;86: 5719-5729.

UCDAVIS HEALTH

Joseph Anderson, Ph.D.

Kambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, Nacey C, McGee J, Lindsey M, Fury B, Bauer G, Nolta J. , Anderson J,. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Molecular Therapy, 2011;19 (3): 584-593.

Anderson J, Nolta J, and Bauer G. Pre-integration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 protein, a CCR5 shRNA, and a TAR decoy. Molecular Therapy, 2009;17: 2103-2114.

Anderson J, Walker J, Nolta J, and Bauer G. Specific Transduction of HIV-Susceptible Cells for CCR5 Knockdown and Resistance to HIV Infection: A Novel Method for Targeted Gene Therapy and Intracellular Immunization. Journal of AIDS, 2009;52(2): 152-161.

Anderson J, Akkina R,. HIV-1 restriction by a human-rhesus chimeric TRIM5alpha in CD34+ cell derived macrophages in vitro and in T cells in vivo in SCID-hu mice transplanted with human tissue. Human Gene Therapy, 2008;19: 217-228.

Anderson J, Akkina R,. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Therapy, 2007;17: 1287 - 1297.

Anderson J, Li MJ, Palmer B, Remling L, Li S, Yam P, Yee JK, Rossi J, Zaia J, and Akkina R. Safety and efficacy of a lentiviral vector containing three anti-HIV genes CCR5 ribozyme, tat-rev siRNA, and TAR decoy in SCID-hu mouse-derived T cells. Molecular Therapy, 2007;6: 1182 - 1188.

Anderson JS. Using TRIM5alpha as an HIV therapeutic: the alpha gene? Expert Opinion on Biological Therapy, 2013;13: 1029-1038.

UCDAVIS HEALTH

Joseph Anderson, Ph.D.

UCDAVIS HEALTH